

Reference list

1. Abdelkefi A, Ben Othman T, Kammoun L. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. *Thrombosis and Haemostasis*. 2004; 92(3):654-661
2. Abdul Sultan A, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. *BMJ*. 2013; 347:f6099
3. Ades AE, Caldwell DM, Reken S, Welton NJ, Sutton AJ, Dias S. Evidence synthesis for decision making 7: a reviewer's checklist. *Medical decision making : an international journal of the Society for Medical Decision Making*. 2013; 33(5):679-691
4. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncology*. 2009; 10(10):943-9
5. Akl EA, Ramly EP, Kahale LA, Yosucio VED, Barba M, Sperati F et al. Anticoagulation for people with cancer and central venous catheters. *Cochrane Database of Systematic Reviews* 2014, Issue 10. Art. No.: CD006468. DOI: 10.1002/14651858.CD006468.pub5.
6. Alikhan R, Bedenis R, Cohen AT. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). *Cochrane Database of Systematic Reviews* 2014, Issue 5. Art. No.: CD003747. DOI: 10.1002/14651858.CD003747.pub4.
7. Anand S, Asumu T. Patient acceptance of a foot pump device used for thromboprophylaxis. *Acta Orthopaedica Belgica*. 2007; 73(3):386-389
8. Apenteng PN, Fitzmaurice D, Litchfield I, Harrison S, Heneghan C, Ward A et al. Patients' perceptions and experiences of the prevention of hospital-acquired thrombosis: a qualitative study. *BMJ Open*. 2016; 6(12):e013839
9. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R et al. Prediction of venous thromboembolism in cancer patients. *Blood*. 2010; 116(24):5377-82
10. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA, Jr., Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. *Annals of Surgery*. 2010; 251(2):344-50
11. Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. *Drug Safety*. 2014; 37(2):79-90
12. Barker SGE, Hollingsworth SJ. Wearing graduated compression stockings: The reality of everyday deep vein thrombosis prophylaxis. *Phlebology*. 2004; 19(1):52-53
13. Bartlett MA, Mauck KF, Daniels PR. Prevention of venous thromboembolism in patients undergoing bariatric surgery. *Vascular Health and Risk Management*. 2015; 11:461-77

14. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. *Lancet*. 2001; 358(9283):702-710
15. Belch JJ, Lowe GDO, Ward AG. Prevention of deep vein thrombosis in medical patients by low-dose heparin. *Scottish Medical Journal*. 1981; 26(2):115-117
16. Bern MM, Bierbaum B, Wetzner S, Brennan W, McAlister S. Very low dose warfarin as prophylaxis against ultrasound detected deep vein thrombosis following primary hip replacement. *American Journal of Hematology*. 2002; 71(2):69-74
17. Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. *PloS One*. 2017; 12(4):e0176283
18. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmieciak TE, Ko CY et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: A decision aid and informed consent tool for patients and surgeons. *Journal of the American College of Surgeons*. 2013; 217(5):833-842.e3
19. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA*. 2005; 293(6):715-22
20. Boehringer Ingelheim. Asantin DVT nach myokardinfarkt (internal report). Bracknell. Boehringer Ingelheim, 1981.
21. Brady D, Raingruber B, Peterson J, Varnau W, Denman J, Resuello R et al. The use of knee-length versus thigh-length compression stockings and sequential compression devices. *Critical Care Nursing Quarterly*. 2007; 30(3):255-262
22. Brismar B, Hardstedt C, Jacobson S, Kager L, Malmborg AS. Reduction of catheter-associated thrombosis in parenteral nutrition by intravenous heparin therapy. *Archives of Surgery*. 1982; 117(9):1196-1199
23. Burrows RF, Gan ET, Gallus AS, Wallace EM, Burrows EA. A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombotic events after caesarean section: a pilot study. *British Journal of Obstetrics and Gynaecology*. 2001; 108(8):835-839
24. Cassidy MR, Rosenkranz P, McAneny D. Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program. *Journal of the American College of Surgeons*. 2014; 218(6):1095-104
25. Catterick D, Hunt BJ. Impact of the national venous thromboembolism risk assessment tool in secondary care in England: retrospective population-based database study. *Blood Coagulation and Fibrinolysis*. 2014; 25(6):571-6
26. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet*. 2010; 376(9758):2075-85
27. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. *Oncologist*. 2017; 22(5):601-608

28. Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. *Thrombosis Research*. 2016; 145:119-125
29. Chan JC, Roche SJ, Lenehan B, O'sullivan M, Kaar K. Compliance and satisfaction with foot compression devices: an orthopaedic perspective. *Archives of Orthopaedic and Trauma Surgery*. 2007; 127(7):567-571
30. Chiou-Tan FY, Garza H, Chan KT, Parsons KC, Donovan WH, Robertson CS et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. *American Journal of Physical Medicine and Rehabilitation*. 2003; 82(9):678-685
31. CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. *Annals of Internal Medicine*. 2010; 153(9):553-562
32. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial. *Lancet Neurology*. 2014; 13(12):1186-1192
33. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Forbes J et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. *Lancet*. 2013; 382(9891):516-524
34. CLOTS Trials Collaboration, Dennis M, Sandercock PAG, Reid J, Graham C, Murray G et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. *Lancet*. 2009; 373(9679):1958-1965
35. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *British Medical Journal*. 2006; 332(7537):325-329
36. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *New England Journal of Medicine*. 2013; 368(6):513-523
37. Colwell CW, Jr., Pulido P, Hardwick ME, Morris BA. Patient compliance with outpatient prophylaxis: An observational study. *Orthopedics*. 2005; 28(2):143-147
38. Conti V, Venegoni M, Cocci A, Fortino I, Lora A, Barbui C. Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control study. *BMC Psychiatry*. 2015; 15:92
39. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE et al. Dalteparin versus unfractionated heparin in critically ill patients. *New England Journal of Medicine*. 2011; 364(14):1305-1314
40. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. *Journal of Clinical Oncology*. 2005; 23(18):4063-4069

41. Cruz M, Fernandez-Alonso AM, Rodriguez I, Garrigosa L, Cano A, Carretero P et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin. *Obstetrics and Gynecology International*. 2011; 2011:548327
42. Cushman M, O'Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR. Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. *Thrombosis Research*. 2016; 144:127-32
43. Dahan R, Houlbert D, Caulin C. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin : a randomized double-blind trial. *Haemostasis*. 1986; 16:159-164
44. Davies SC. Annual Report of the Chief Medical Officer, 2014: The health of the 51%: Women. London. Department of Health, 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/595439/CMO_annual_report_2014.pdf
45. De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. *Annals of Oncology*. 2009; 20(12):1936-42
46. den Ottolander GJH, van der Mass APC, Veen MR. The preventive value against venous thrombosis by treatment with ASA and RA-233 in patients with decompensated heart disease. Washington. Proceedings of III congress of International Society for Thrombosis and Haemostasis, 1972.
47. Dennis M, Graham C, Smith J, Forbes J, Sandercock P. Which stroke patients gain most from intermittent pneumatic compression: Further analyses of the CLOTS 3 trial. *International Journal of Stroke*. 2015; 10(A100):103-107
48. Dennis M, Sandercock P, Graham C, Forbes J, Smith J. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. *Health Technology Assessment*. 2015; 19(76):1-90
49. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. *Cochrane Database Syst Rev* 2016, Issue 12. Art. No.: CD008500. DOI: 10.1002/14651858.CD008500.pub4.
50. Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment. *Medical decision making : an international journal of the Society for Medical Decision Making*. 2013; 33(5):618-640
51. Diener HC, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Harenberg J et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. *Stroke*. 2006; 37(1):139-144
52. Duke RJ, Turpie AGG, Bloch RF, Trebilcock RG. Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-

- evolution. 'In:' Reivich M, Hurtig HI, editors. Cerebrovascular disease. New York, NY: Raven Press. 1983. p. 399-405.
53. Edmonds MJR, Crichton TJH, Runciman WB, Pradhan M. Evidence-based risk factors for postoperative deep vein thrombosis. *ANZ Journal of Surgery*. 2004; 74(12):1082-1097
54. Fraisse F, Holzapfel L, Couland JM. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. *American Journal of Respiratory and Critical Care Medicine*. 2000; 161(4):1109-1114
55. Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O'Brien SE, Carroll JJ et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. *New England Journal of Medicine*. 1973; 288(11):545-551
56. Gardner AM, Fox RH. The venous pump of the human foot--preliminary report. *Bristol MedChirJ*. 1983; 98(367):109-112
57. Gates S, Brocklehurst P, Ayers S, Bowler U, Group. TiPA. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. *American Journal of Obstetrics and Gynecology*. 2004; 191(4):1296-1303
58. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). *Chest*. 2008; 133(6 Suppl):381S-453S
59. Germini F, Agnelli G, Fedele M, Galli MG, Giustozzi M, Marcucci M et al. Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. *Journal of Thrombosis and Thrombolysis*. 2016; 42(3):336-9
60. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *New England Journal of Medicine*. 2011; 365(23):2167-2177
61. Goucke CR. Prophylaxis against venous thromboembolism. *Anaesthesia and Intensive Care*. 1989; 17(4):458-465
62. GRADE Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group website. 2011. Available from: <http://www.gradeworkinggroup.org/> Last accessed: 15/08/17.
63. Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA. Assessing the Caprini score for risk assessment of venous thromboembolism in hospitalized medical patients. *American Journal of Medicine*. 2016; 129(5):528-35
64. Greene MT, Spyropoulos AC, Chopra V, Grant PJ, Kaatz S, Bernstein SJ et al. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. *The American Journal of Medicine*. 2016; 129(9):1001.e9–1001.e18
65. Gregory PC, Kuhlemeier KV. Prevalence of venous thromboembolism in acute hemorrhagic and thromboembolic stroke. *American Journal of Physical Medicine and Rehabilitation*. 2003; 82(5):364-369
66. Haas S, Schellong SM, Tebbe U, Gerlach HE, Bauersachs R, Melzer N et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. *BMC Cancer*. 2011; 11:316

67. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. *Clinical and Applied Thrombosis/Hemostasis*. 2012; 18(2):159-65
68. Hachey KJ, Hewes PD, Porter LP, Ridyard DG, Rosenkranz P, McAneny D et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. *Journal of Thoracic and Cardiovascular Surgery*. 2016; 151(1):37-44.e1
69. Haddad FS, Kerry RM, McEwen JA, Appleton L, Garbuz DS, Masri BA et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: A possible source of variation in reported patient outcomes. *Journal of Arthroplasty*. 2001; 16(1):37-46
70. Handley AJ, Emerson PA, Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction. *British Medical Journal*. 1972; 2(5811):436-438
71. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention thromboembolism in medical inpatients. *Haemostasis*. 1996; 26(3):127-139
72. Health and Social Care Information Centre. Statistics on Obesity, Physical Activity and Diet. 2016. Available from: <http://content.digital.nhs.uk/catalogue/PUB20562/obes-phys-acti-diet-eng-2016-rep.pdf>
73. Health Do. Risk assessment tool for venous thromboembolism (VTE). 2010. Available from: http://webarchive.nationalarchives.gov.uk/20130123195034/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088215 Last accessed:
74. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. *Internal Medicine Journal*. 2002; 32(3):84-88
75. Hegsted D, Gritsiouk Y, Schlesinger P, Gardiner S, Gubler KD. Utility of the risk assessment profile for risk stratification of venous thrombotic events for trauma patients. *American Journal of Surgery*. 2013; 205(5):517-20; discussion 520
76. Heilmann L, Rath W, Pollow K, Bick RL. The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood. *Clinical Hemorheology and Microcirculation*. 2007; 37(3):211-218
77. Hewes PD, Hachey KJ, Zhang XW, Tripodis Y, Rosenkranz P, Ebright MI et al. Evaluation of the Caprini model for venothromboembolism in esophagectomy patients. *Annals of Thoracic Surgery*. 2015; 100(6):2072-8
78. Hillbom M, Eriola T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double blind study. *Acta Neurologica Scandinavica*. 2002; 106(2):84-92
79. Ho KM, Rao S, Rittenhouse KJ, Rogers FB. Use of the Trauma Embolic Scoring System (TESS) to predict symptomatic deep vein thrombosis and fatal and non-fatal pulmonary embolism in severely injured patients. *Anaesthesia and Intensive Care*. 2014; 42(6):709-14
80. Hostler DC, Marx ES, Moores LK, Petteys SK, Hostler JM, Mitchell JD et al. Validation of the international medical prevention registry on venous thromboembolism bleeding risk score. *Chest*. 2016; 149(2):372-9

81. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Annals of Internal Medicine*. 2010; 153(1):8-18
82. Ishi SV, Lakshmi M, Kakde ST, Sabnis KC, Jagannati M, Girish TS et al. Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis. *Journal of the Association of Physicians of India*. 2013; 61(12):882-886
83. Janvrin SB, Davies G, Greenhalgh RM. Postoperative deep vein thrombosis caused by intravenous fluids during surgery. *British Journal of Surgery*. 1980; 67(10):690-693
84. Johnson MJ, McMillan B, Fairhurst C, Gabe R, Ward J, Wiseman J et al. Primary thromboprophylaxis in hospices: the association between risk of venous thromboembolism and development of symptoms. *Journal of Pain and Symptom Management*. 2014; 48(1):56-64
85. Joint Formulary Committee. *British National Formulary 56*. London. British Medical Association and Royal Pharmaceutical Society of Great Britain. 2008.
86. Jorgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venographic controlled study. *Thrombosis Research*. 2002; 105(6):477-480
87. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. *New England Journal of Medicine*. 2011; 365(26):2463-2472
88. Karthaus M, Kretzschmar A, Kroning H. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. *Annals of Oncology*. 2006; 17(2):289-296
89. Kelly J, Hunt BJ, Lewis RR, Swaminathan R, Moody A, Seed PT et al. Dehydration and venous thromboembolism after acute stroke. *Quarterly Journal of Medicine*. 2004; 97(5):293-296
90. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. *British Medical Journal*. 2001; 323(7305):131-134
91. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood*. 2008; 111(10):4902-7
92. Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. *European Heart Journal*. 1993; 14(10):1365-1368
93. Kierkegaard A, Norgren L, Olsson CG, Castenfors J, Persson G, Persson S. Incidence of deep vein thrombosis in bedridden non-surgical patients. *Acta Medica Scandinavica*. 1987; 222(5):409-414
94. Kleber FX, Witt C, Vogel G. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *American Heart Journal*. 2003; 145(4):614-621
95. Lacut K, Bressollette L, Le Gal G, Etienne E, De Tinteniatic A, Renault A et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. *Neurology*. 2005; 65(6):865-869

96. Larocca A, Cavallo F, Bringham S, Di Raimondo F, Falanga A, Evangelista A et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood*. 2012; 119(4):933-1093
97. Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Venat-Bouvet L et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. *Cancer Chemotherapy and Pharmacology*. 2013; 72(1):65-73
98. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. *Haemostasis*. 1996; 26(Suppl 2):49-56
99. Lecumberri R, Panizo E, Gomez-Guiu A, Varea S, Garcia-Quetglas E, Serrano M et al. Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. *Journal of Thrombosis and Haemostasis*. 2011; 9(6):1108-1115
100. Lederle FA, Sacks JM, Fiore L, Landefeld CS, Steinberg N, Peters RW. The prophylaxis of medical patients for thromboembolism pilot study. *American Journal of Medicine*. 2006; 119(1):54-59
101. Leizorovicz A, Cohen AT, Turpie AGG. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*. 2004; 110(7):874-879
102. Lester W, Freemantle N, Begaj I, Ray D, Wood J, Pagano D. Fatal venous thromboembolism associated with hospital admission: a cohort study to assess the impact of a national risk assessment target. *Heart*. 2013; 99(23):1734-9
103. Levine M, Hirsh J, Gent M. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. *Lancet*. 1994; 343(8902):886-889
104. Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. *Journal of Thrombosis and Haemostasis*. 2012; 10(5):807-814
105. Liu LP, Zheng HG, Wang DZ, Wang YL, Hussain M, Sun HX et al. Risk assessment of deep-vein thrombosis after acute stroke: a prospective study using clinical factors. *CNS Neuroscience & Therapeutics*. 2014; 20(5):403-10
106. Lobastov K, Barinov V, Schastlivtsev I, Laberko L, Rodoman G, Boyarintsev V. Validation of the Caprini risk assessment model for venous thromboembolism in high-risk surgical patients in the background of standard prophylaxis. *Journal of Vascular Surgery*. 2016; 4(2):153-60
107. Macoviak JA, Melnik G, McLean G. The effect of the low-dose heparin on the prevention of venous thrombosis in patients receiving short-term parenteral nutrition. *Current Surgery*. 1984; 41:98-100
108. Mahe I, Bergmann JF, d'Azemar P, JJ V, Caulin C. Lack of effect of low molecular weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double blind study. *European Journal of Clinical Pharmacology*. 2005; 61(5-6):347-351
109. Marsh N. *Fibrinolysis*. Chichester. John Wiley & Sons. 1981.

110. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. *Obstetrics and Gynecology*. 2001; 98(6):989-995
111. May V, Clarke T, Coulling S, Cowie L, Cox R, Day D et al. What information patients require on graduated compression stockings. *British Journal of Nursing*. 2006; 15(5):263-270
112. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. *Age and Ageing*. 1986; 15(2):84-88
113. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. *Lancet*. 1977; 310(8042):800-801
114. Medicines and Healthcare products Regulatory Agency. The risk of venous thromboembolism associated with antipsychotics. Medicines and Healthcare products Regulatory Agency, 2009. Available from: <http://www.mhra.gov.uk/home/groups/s-par/documents/websiteresources/con079334.pdf>
115. Millar JA, Gee AL. Estimation of clinical and economic effects of prophylaxis against venous thromboembolism in medical patients, including the effect of targeting patients at high-risk. *Internal Medicine Journal*. 2016; 46(3):315-24
116. The Million Women Study: design and characteristics of the study population. The Million Women Study Collaborative Group. *Breast Cancer Research*. 1999; 1(1):73-80
117. Miranda S, Le Cam-Duchez V, Benichou J, Donnadieu N, Barbay V, Le Besnerais M et al. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study. *Thrombosis Research*. 2017; 155:1-5
118. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. *British Journal of Surgery*. 2001; 88(7):913-930
119. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R. Upper extremity deep vein thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). *Thrombosis and Haemostasis*. 1996; 75:251-253
120. Morgan ES, Wilson E, Watkins T, Gao F, Hunt BJ. Maternal obesity and venous thromboembolism. *International Journal of Obstetric Anesthesia*. 2012; 21(3):253-63
121. Muir KW, Watt A, Baxter G, Grosset DG, Lees KR. Randomized trial of graded compression stockings for prevention of deep vein thrombosis after acute stroke. *Quarterly Journal of Medicine*. 2000; 93(6):359-364
122. Murakami M, McDill TL, Cindrick-Pounds C. Deep vein thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. *Journal of Vascular Surgery*. 2003; 38(5):923-927
123. Najafzadeh M, Kim SC, Patterson C, Schneeweiss S, Katz JN, Brick GW et al. Patients' perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: a qualitative study. *BMC Musculoskeletal Disorders*. 2015; 16:319
124. National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) inpatients admitted to

- hospital. NICE clinical guideline 92. London. National Clinical Guideline Centre, 2010. Available from: <http://www.nice.org.uk/CG92>
125. National Collaborating Centre for Acute Care. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guideline CG46. London. National Institute for Health and Clinical Excellence, 2007. Available from: <http://guidance.nice.org.uk/CG46>
126. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
127. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance 157. London. National Institute for Health and Clinical Excellence, 2008. Available from: <http://guidance.nice.org.uk/TA157>
128. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London. National Institute for Health and Clinical Excellence, 2008. Available from: <https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf>
129. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism. NICE technology appraisal guidance 170. London. National Institute for Health and Clinical Excellence, 2009. Available from: <http://guidance.nice.org.uk/TA170>
130. National Institute for Health and Clinical Excellence. Venous thromboembolism in adults: reducing the risk in hospital. NICE quality standard 3. London. National Institute for Health and Clinical Excellence, 2010. Available from: <http://guidance.nice.org.uk/QS3>
131. National Institute for Health and Clinical Excellence. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245. London. National Institute for Health and Clinical Excellence, 2012. Available from: <http://guidance.nice.org.uk/TA245>
132. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. 2nd ed. London. National Institute for Health and Clinical Excellence, 2013. Available from: <http://publications.nice.org.uk/pmg9>
133. Nendaz M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH et al. Multicentre validation of the Geneva risk score for hospitalised medical patients at risk of venous thromboembolism. Explicit assessment of thromboembolic risk and prophylaxis for medical patients in Switzerland (ESTIMATE). *Thrombosis and Haemostasis*. 2014; 111(3):531-8
134. NHS England. NHS Services, Seven Days a Week Forum: evidence base and clinical standards for the care and onward transfer of acute inpatients. 2013;
135. NHS Improving Quality. Intermittent Pneumatic Compression (IPC) sleeves Programme FAQs. 2014. Available from: http://webarchive.nationalarchives.gov.uk/20160506191837/http://www.nhs.uk/medi a/2463598/ipc_sleeves_faqs_v1_290514.pdf
136. Niers TM, Di Nisio M, Klerk CP, Baarslag HJ, Buller HR, Biemond BJ. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for

- hematologic malignancies: a randomized, placebo-controlled study. *Journal of Thrombosis and Haemostasis*. 2007; 5(9):1878-1882
137. Noble S, Prout H, Nelson A. Patients' Experiences of Living with CANcer-associated thrombosis: the PELICAN study. *Patient Preference and Adherence*. 2015; 9:337-45
138. Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. *BMJ*. 2006; 332(7541):577-580
139. Novielli N, Cooper NJ, Abrams KR, Sutton AJ. How is evidence on test performance synthesized for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997. *Value in Health*. 2010; 13(8):952-957
140. Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V et al. Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients. *JAMA surgery*. 2015; 150(10):941-8
141. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2012. Available from: <http://www.oecd.org/std/ppp> Last accessed: 09/05/2016.
142. Pagella P, Cipolle M, Sacco E, Matula P, Karoly E, Bokovoy J. A randomized trial to evaluate compliance in terms of patient comfort and satisfaction of two pneumatic compression devices. *Orthopaedic Nursing*. 2007; 26(3):169-174
143. Palumbo A, Brinchen S, Rossi D, Cavalli M, Larocca A, Ria R et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. *Journal of Clinical Oncology*. 2010; 28(34):5101-9
144. Palumbo A, Cavo M, Brinchen S, Zamagni E, Romano A, Patriarca F et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *Journal of Clinical Oncology*. 2011; 29(8):986-993
145. Pambianco G, Orchard T, Landau P. Deep vein thrombosis: prevention in stroke patients during rehabilitation. *Archives of Physical Medicine and Rehabilitation*. 1995; 76(4):324-330
146. Pannucci CJ, Laird S, Dimick JB, Campbell DA, Henke PK. A validated risk model to predict 90-day VTE events in postsurgical patients. *Chest*. 2014; 145(3):567-73
147. Pannucci CJ, Osborne NH, Wahl WL. Creation and validation of a simple venous thromboembolism risk scoring tool for thermally injured patients: analysis of the National Burn Repository. *Journal of Burn Care & Research*. 2012; 33(1):20-5
148. Pannucci CJ, Shanks A, Moote MJ, Bahl V, Cederna PS, Naughton NN et al. Identifying patients at high risk for venous thromboembolism requiring treatment after outpatient surgery. *Annals of Surgery*. 2012; 255(6):1093-9
149. Parnaby C. A new anti-embolism stocking. Use of below-knee products and compliance. *British Journal of Perioperative Nursing*. 2004; 14(7):302-304
150. Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. *American Journal of Hematology*. 2017; 92(6):501-507

151. Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: Outcomes from the CONKO-004 trial. *Journal of Clinical Oncology*. 2015; 33(18):2028-2034
152. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. *Journal of Thrombosis and Haemostasis*. 2010; 8(9):1959-1965
153. Pitt A, Anderson ST, Habersberger PG, Rosengarten DS. Low dose heparin in the prevention of deep-vein thromboses in patients with acute myocardial infarction. *American Heart Journal*. 1980; 99(5):574-578
154. Pitto RP, Young S. Foot-pumps without graduated compression stockings for prevention of deep-vein thrombosis in total joint replacement: Efficacy, safety and patient compliance - A comparative, prospective clinical trial. *International Orthopaedics*. 2008; 32(3):337
155. Pitto RP, Young S. Foot pumps without graduated compression stockings for prevention of deep-vein thrombosis in total joint replacement: efficacy, safety and patient compliance. A comparative, prospective clinical trial. *International Orthopaedics*. 2008; 32(3):331-336
156. Prasad BK, Banerjee AK, Howard H. Incidence of deep vein thrombosis and the effect of pneumatic compression of the calf in elderly hemiplegics. *Age and Ageing*. 1982; 11(1):42-44
157. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJH. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. *Haemostasis*. 1989; 19(5):245-250
158. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *Journal of Clinical Epidemiology*. 2005; 58(10):982-990
159. Review Manager (RevMan) [Computer program]. Version 5. Copenhagen. The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. Available from: <http://tech.cochrane.org/Revman>
160. Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauer C, Sieder C et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. *Journal of Thrombosis and Haemostasis*. 2010; 8(6):1209-1215
161. Roberts LN, Durkin M, Arya R. Annotation: Developing a national programme for VTE prevention. *British Journal of Haematology*. 2017; 178(1):162-170
162. Roberts LN, Porter G, Barker RD, Yorke R, Bonner L, Patel RK et al. Comprehensive VTE prevention program incorporating mandatory risk assessment reduces the incidence of hospital-associated thrombosis. *Chest*. 2013; 144(4):1276-81
163. Robertson KA, Bertot AJ, Wolfe MW, Barrack RL. Patient compliance and satisfaction with mechanical devices for preventing deep venous thrombosis after joint replacement. *Journal of the Southern Orthopaedic Association*. 2000; 9(3):182-186
164. Rogers FB, Shackford SR, Horst MA, Miller JA, Wu D, Bradburn E et al. Determining venous thromboembolic risk assessment for patients with trauma: the trauma embolic scoring system. *Journal of Trauma and Acute Care Surgery*. 2012; 73(2):511-5

165. Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP. Risk factor model to predict venous thromboembolism in hospitalized medical patients. *Journal of Hospital Medicine*. 2011; 6(4):202-9
166. Royal College of Obstetricians and Gynaecologists. Hormone replacement therapy and venous thromboembolism (Guideline No. 19) <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg19/> 2004, Issue
167. Royal College of Obstetricians and Gynaecologists. Thromboprophylaxis during pregnancy, labour and after vaginal delivery (Guideline No. 37). http://www.rcog.org.uk/resources/Public/pdf/Thromboprophylaxis_no037.pdf 2004, Issue
168. Royal College of Obstetricians and Gynaecologists. Thrombosis and embolism during pregnancy and the puerperium, reducing the risk. Green-top Guideline No. 37a. London. Royal College of Obstetricians and Gynaecologists, 2015. Available from: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/>
169. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. *New England Journal of Medicine*. 1999; 341(11):793-800
170. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. *Seminars in Thrombosis and Hemostasis*. 1990; 16(Suppl):25-33
171. Santamaria A, Ugarriza A, Munoz C, De D, I, Lopez-Chulia F, Benet C et al. Bemiparin versus unfractionated heparin as bridging therapy in the perioperative management of patients on vitamin K antagonists: The BERTA study. *Clinical Drug Investigation*. 2013; 33(12):921-928
172. Schellong SM, Gerlach H-E, Tebbe U, Haas S, Abletshauser C, Sieder C et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. *Hamostaseologie*. 2011; 31(1):A87
173. Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. *Expert Opinion on Pharmacotherapy*. 2010; 11(18):2953-2961
174. Segal S, Sadovsky E, Weinstein D, Polishuk WZ. Prevention of postpartum venous thrombosis with low doses of heparin. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*. 1975; 5(5):273-6
175. Shaikh MA, Jeong HS, Mastro A, Davis K, Lysikowski J, Kenkel JM. Analysis of the American Society of Anesthesiologists Physical Status Classification System and Caprini Risk Assessment Model in predicting venous thromboembolic outcomes in plastic surgery patients. *Aesthetic Surgery Journal*. 2016; 36(4):497-505
176. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. *Lancet*. 2007; 369(9570):1347-1355
177. Sigel B, Edelstein AL, Felix WR, Jr., Memhardt CR. Compression of the deep venous system of the lower leg during inactive recumbency. *Archives of Surgery*. 1973; 106(1):38-43

178. Spahn G. Compliance with self-administration of heparin injections in outpatients. *European Journal of Trauma*. 2002; 28(2):104-109
179. Spyropoulos AC, Anderson FA, Jr., Fitzgerald G, Decousus H, Pini M, Chong BH et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. *Chest*. 2011; 140(3):706-14
180. Stephenson ML, Serra AE, Neepner JM, Caballero DC, McNulty J. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. *Journal of Perinatology*. 2016; 36(2):95-9
181. Stewart D, Zalamea N, Waxman K, Schuster R, Bozuk M. A prospective study of nurse and patient education on compliance with sequential compression devices. *American Surgeon*. 2006; 72(10):921-923
182. Storti S, Crucitti P, Cina G. Risk factors and prevention of venous thromboembolism. *Rays*. 1996; 21(3):439-460
183. Sultan AA, West J, Grainge MJ, Riley RD, Tata LJ, Stephansson O et al. Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study. *BMJ*. 2016; 355:i6253
184. Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshaus C, Sieder C et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. *American Heart Journal*. 2011; 161(2):322-328
185. Van Blerk D. Evaluating an intermittent compression system for thromboembolism prophylaxis. *Professional Nurse*. 2004; 20(4):48-49
186. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahe I et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. *Haematologica*. 2017; Epublication
187. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. *Statistics in Medicine*. 2002; 21(4):589-624
188. Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. *Statistics in Medicine*. 1993; 12(24):2273-2284
189. Vardi M, Ghanem-Zoubi NO, Zidan R, Yurin V, Bitterman H. Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments. *Journal of Thrombosis and Haemostasis*. 2013; 11(3):467-73
190. Vaziri S, Wilson J, Abbatematteo J, Kubilis P, Chakraborty S, Kshitij K et al. Predictive performance of the American College of Surgeons universal risk calculator in neurosurgical patients. *Journal of Neurosurgery*. 2017:1-6
191. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. *Journal of Clinical Oncology*. 2005; 23(18):4057-4062
192. Vignon P, Dequin PF, Renault A, Mathonnet A, Paleiron N, Imbert A et al. Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of

- bleeding hospitalized in intensive care units: the CIREA1 randomized trial. *Intensive Care Medicine*. 2013; 39(5):872-880
193. Wang Y, Attar BM, Fuentes HE, Yu J, Zhang H, Tafur AJ. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma. *Clinical and Applied Thrombosis/Hemostasis*. 2017:1076029617699088
194. Warlow C. Venous thromboembolism after stroke. *American Heart Journal*. 1978; 96(3):283-285
195. Warlow C, Beattie AG, Terry G, Ogston D, Kenmure ACF, Douglas AS. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. *Lancet*. 1973; 302(7835):934-936
196. Watson HG, Keeling DM, Laffan M, Tait RC, Makris M, British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. *British Journal of Haematology*. 2015; 170(5):640-8
197. Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G et al. Global public awareness of venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2015; 13(8):1365-71
198. Westrich GH, Jhon PH, Sánchez PM. Compliance in using a pneumatic compression device after total knee arthroplasty. *American Journal of Orthopedics*. 2003; 32(3):135-140
199. Wilbur K, Lynd LD, Sadatsafavi M. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmaco-economic analysis. *Clinical and Applied Thrombosis/Hemostasis*. 2011; 17(5):454-465
200. WinBUGS [Computer programme] version 1.4. Cambridge. MRC Biostatistics Unit UoC, 2015. Available from: <http://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/>
201. Winoker JS, Paulucci DJ, Anastos H, Waingankar N, Abaza R, Eun DD et al. Predicting complications following robot-assisted partial nephrectomy with the ACS-NSQIP Universal Surgical Risk Calculator. *Journal of Urology*. 2017; Epublication
202. Woller SC, Stevens SM, Jones JP, Lloyd JF, Evans RS, Aston VT et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. *American Journal of Medicine*. 2011; 124(10):947-954.e2
203. Wood KB, Kos PB, Abnet JK, Ista C. Prevention of deep-vein thrombosis after major spinal surgery: a comparison study of external devices. *Journal of Spinal Disorders*. 1997; 10(3):209-214
204. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. *Lancet*. 2009; 373(9663):567-574